Prostate Cancer - Results from #28640

PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: Impact on hemiablative focal therapy - Abstract February 9, 2011

Dutasteride not a cost-effective way to prevent prostate cancer in some February 9, 2011

Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study - Abstract February 8, 2011

Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid - Abstract February 8, 2011

5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression - Abstract February 8, 2011

Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer - Abstract February 8, 2011

Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers - Abstract February 8, 2011

Vitamin D deficiency promotes prostate cancer growth in bone - Abstract February 8, 2011

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the Department of Defense prostate cancer clinical trials consortium - Abstract February 8, 2011

33% radius evaluation to assess bone mineral density in prostate cancer patients - Abstract February 8, 2011

Use and evaluation of a CD-ROM-based decision aid for prostate cancer treatment decisions - Abstract February 7, 2011

Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer - Abstract February 7, 2011

A review of African American-white differences in risk factors for cancer: Prostate cancer - Abstract February 7, 2011

Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer - Abstract February 7, 2011

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: Technique, early toxicity, and PSA response - Abstract February 7, 2011

Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: Can ADC values contribute to assess the aggressiveness of prostate cancer? - Abstract February 7, 2011

Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer - Abstract February 7, 2011

Active surveillance for localized prostate cancer--current practices and recommendations - Abstract February 4, 2011

Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity - Abstract February 4, 2011

Initial treatment costs of organ-confined prostate cancer: A general perspective - Abstract February 4, 2011

Page 1433 of 1436